Business & Finance
Gilead Sciences to increase production of Remdesivir in India to tackle the growing COVID-19 crisis
27 April 2021 -

Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) said on Monday that it is expanding its new local manufacturing facilities as well providing active pharmaceutical ingredient (API) to rapidly scale up production of remdesivir in response to the rapid increase in COVID-19 cases in India.

The company added that it will also donate at least 450,000 vials of Veklury (remdesivir) to the Government of India to help address the immediate needs of Indian patients. All seven of licensees based in India have significantly accelerated production of remdesivir by scaling up their batch sizes, adding new manufacturing facilities and/or onboarding local contract manufacturers across the country.

Established in May 2020, the company's voluntary licensing programme for remdesivir has enabled access to the drug for 2.3m people in more than 60 low- and middle-income countries. The programme provides long-term licenses to nine manufacturers, seven of which are based in India, to enable access to remdesivir in 127 countries, most of which are low- and low-middle income countries, including India.

Remdesivir, a nucleotide analog invented by Gilead, has broad-spectrum antiviral activity both in vitro and in vivo in animal models against multiple emerging viral pathogens, including Ebola, SARS, Marburg, MERS and SARS-CoV-2, the virus that causes COVID-19.